Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors with high progranulin expression
Fig 3
Recurrence or progression-free survival (A) and overall survival (B) according to initial status; recurrence-free survival (C) in non-metastatic gastrointestinal stromal tumors (GISTs) and progression-free survival (D) in metastatic GISTs according to progranulin (PGRN) expression; recurrence-free survival in non-metastatic GISTs according to modified National Institutes of Health (NIH) classification (E) and modified NIH/PGRN expression (F).